- Home
- ROIV vs GTLS Comparison
ROIV vs GTLS Comparison
Compare ROIV & GTLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ROIV
- GTLS
- Stock Information
- Founded
- ROIV 2014
- GTLS 1859
- Country
- ROIV United Kingdom
- GTLS United States
- Employees
- ROIV N/A
- GTLS N/A
- Industry
- ROIV Biotechnology: Pharmaceutical Preparations
- GTLS Metal Fabrications
- Sector
- ROIV Health Care
- GTLS Industrials
- Exchange
- ROIV Nasdaq
- GTLS Nasdaq
- Market Cap
- ROIV 8.6B
- GTLS 9.0B
- IPO Year
- ROIV N/A
- GTLS 1992
- Fundamental
- Price
- ROIV $14.08
- GTLS $199.23
- Analyst Decision
- ROIV Strong Buy
- GTLS Buy
- Analyst Count
- ROIV 4
- GTLS 14
- Target Price
- ROIV $15.50
- GTLS $200.50
- AVG Volume (30 Days)
- ROIV 6.6M
- GTLS 1.6M
- Earning Date
- ROIV 11-11-2025
- GTLS 10-31-2025
- Dividend Yield
- ROIV N/A
- GTLS N/A
- EPS Growth
- ROIV N/A
- GTLS 176.90
- EPS
- ROIV N/A
- GTLS 5.39
- Revenue
- ROIV $23,233,000.00
- GTLS $4,253,100,000.00
- Revenue This Year
- ROIV N/A
- GTLS $12.49
- Revenue Next Year
- ROIV $281.14
- GTLS $9.94
- P/E Ratio
- ROIV N/A
- GTLS $36.50
- Revenue Growth
- ROIV N/A
- GTLS 8.95
- 52 Week Low
- ROIV $8.73
- GTLS $104.60
- 52 Week High
- ROIV $14.48
- GTLS $220.03
- Technical
- Relative Strength Index (RSI)
- ROIV 76.40
- GTLS 66.07
- Support Level
- ROIV $11.85
- GTLS $198.71
- Resistance Level
- ROIV $14.48
- GTLS $199.97
- Average True Range (ATR)
- ROIV 0.42
- GTLS 0.70
- MACD
- ROIV 0.21
- GTLS -0.86
- Stochastic Oscillator
- ROIV 86.26
- GTLS 69.59
About ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.
About GTLS Chart Industries Inc.
Chart Industries provides a variety of cryogenic equipment for storage, distribution, and other processes within the industrial gas and liquefied natural gas industries. It also provides natural gas processing solutions for the natural gas industry and specialty products that serve a variety of spaces, including hydrogen, biofuels, cannabis, and water treatment. The firm acquired Howden in a significant deal in early 2023, roughly doubling the size of the company. It plans to merge with Flowserve by the end of 2025.